Analyst Optimistic on Terns (TERN) Citing Possible $4.8B Market for Upcoming Leukemia Drug

Terns Pharmaceuticals Inc. (NASDAQ:TERN) is one of 15 stocks with the biggest hedge fund momentum, after gaining 42 hedge fund holders during the fourth quarter of 2025. On February 9, Leerink Partners initiated coverage on Terns Pharmaceuticals Inc. (NASDAQ:TERN) with an Outperform rating and a price target of $58. Leerink Partners noted that TERN-701, Terns Pharmaceuticals Inc. (NASDAQ:TERN)’s next-generation allosteric inhibitor being developed for chronic myeloid leukemia, addresses a market with est ...